Contributing to Global Animal Health
One of our main activities is to work as Designated Marketing Authorization Holder (D-MAH) for foreign animal health manufacturers that don’t have any subsidiaries in Japan.
According to JMAFF’s product database, AHRMS received a needle free injector for pigs as D-MAH on Feb. 8, 2021.
https://www.vm.nval.go.jp/public/detail/18635 (Sorry in Japanese)
Osaka-based Senju Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Osaka, President: Shuhei Yoshida, hereinafter “Senju Pharmaceutical”) and DS Pharma Animal Health Co., Ltd. will release “IDU Senju (R) “, an eye drops for cat herpesvirus infections, which Senju Pharmaceutical obtained marketing approval in December 2020, and will release it on May 19, 2021.
“Senju Pharmaceutical launched “IDU Senju®” eye drops for feleine herpesvirus through DS Pharma Animal Health.” の続きを読む
DS Pharma Animal Health Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; President & CEO: Kazuhiro Takada) announced today that it received marketing authorization on March 19 for Stemcure® (development code: A-110), a canine allogeneic adipose tissue-derived mesenchymal stem cell product that is classified as a veterinary regenerative medical product (animal somatic stem cell-processed product). This is the world’s first authorization approval for the manufacture and marketing of a veterinary regenerative medical product whose main ingredient is canine allogeneic adipose tissue-derived mesenchymal stem cells.
You can download the press release from the link below:
https://animal.ds-pharma.co.jp/html/english/pdf/press_210322b.pdf